BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34330766)

  • 1. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.
    Monga V; Miller BJ; Tanas M; Boukhar S; Allen B; Anderson C; Stephens L; Hartwig S; Varga S; Houtman J; Wang L; Zhang W; Jaber O; Thomason J; Kuehn D; Rajput M; Metz C; Zamba KD; Mott S; Abanonu C; Bhatia S; Milhem M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
    Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP
    JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
    Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
    J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
    Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS
    Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer.
    Soliman H; Hogue D; Han H; Mooney B; Costa R; Lee MC; Niell B; Williams A; Chau A; Falcon S; Khakpour N; Weinfurtner RJ; Hoover S; Kiluk J; Rosa M; Khong H; Czerniecki B
    Clin Cancer Res; 2021 Feb; 27(4):1012-1018. PubMed ID: 33219014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.
    MacArthur TA; Fahy AS; Jakub JW
    Am Surg; 2021 Jun; 87(6):849-854. PubMed ID: 34060947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
    Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM
    J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
    Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
    BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
    Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
    Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
    Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
    J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas.
    Bonvalot S; Le Pechoux C; De Baere T; Kantor G; Buy X; Stoeckle E; Terrier P; Sargos P; Coindre JM; Lassau N; Ait Sarkouh R; Dimitriu M; Borghi E; Levy L; Deutsch E; Soria JC
    Clin Cancer Res; 2017 Feb; 23(4):908-917. PubMed ID: 27998887
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
    Canter RJ; Borys D; Olusanya A; Li CS; Lee LY; Boutin RD; Christensen SD; Tamurian RM; Monjazeb AM
    Ann Surg Oncol; 2014 May; 21(5):1616-23. PubMed ID: 24554062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy.
    Casale F; Tchanque-Fossuo C; Stepenaskie S; Durkin J
    Dermatol Online J; 2022 Jan; 28(1):. PubMed ID: 35499413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margin.
    Alekhteyar KM; Leung DH; Brennan MF; Harrison LB
    Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):321-4. PubMed ID: 8892454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma.
    Henning A; Agnese D; Chung CG
    J Cutan Pathol; 2021 Nov; 48(11):1423-1426. PubMed ID: 34189749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complications and short-term outcomes of intraoperative electron radiotherapy (IOERT) in patients with periarticular soft-tissue sarcomas of the extremities].
    Fan CC; Feng QF; Zhai YR; Li MH; Xu LB; Zhao ZG; Chen XY; Hu ZH; Zhang YQ; Yu SJ
    Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):311-5. PubMed ID: 22781047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral oncolytic immunotherapy in the war on cancer: Infection control considerations.
    Robilotti EV; Kumar A; Glickman MS; Kamboj M
    Infect Control Hosp Epidemiol; 2019 Mar; 40(3):350-354. PubMed ID: 30767816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study.
    Bonvalot S; Wunder J; Gronchi A; Broto JM; Turcotte R; Rastrelli M; Papai Z; Radaelli S; Lindner LH; Shumelinsky F; Cubillo A; Rutkowski P; Demaire C; Strens D; Nalbantov G
    Eur J Surg Oncol; 2021 Aug; 47(8):2166-2172. PubMed ID: 33676792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.
    Finkelstein SE; Iclozan C; Bui MM; Cotter MJ; Ramakrishnan R; Ahmed J; Noyes DR; Cheong D; Gonzalez RJ; Heysek RV; Berman C; Lenox BC; Janssen W; Zager JS; Sondak VK; Letson GD; Antonia SJ; Gabrilovich DI
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):924-32. PubMed ID: 21398051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
    Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
    Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.